Merck $MRK beat on the top &amp; bottom lines in Q1, with sales +11% to $12.1 bln &amp; GAAP net income +10% to $3.2 bln. But MRK -3.3% as it lowered full-year guidance due to COVID-19. Flagship immuno-oncology drug Keytruda sales +45% to $3.3 bln. MRK P/E 14.8x, dividend 3.0%.

#stocks https://t.co/TiaUPddA0Y